| Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity Z Adhireksan, GE Davey, P Campomanes, M Groessl, CM Clavel, H Yu, ... Nature communications 5 (1), 3462, 2014 | 319 | 2014 |
| Organometallic ruthenium (II) arene compounds with antiangiogenic activity P Nowak-Sliwinska, JR van Beijnum, A Casini, AA Nazarov, G Wagnieres, ... Journal of medicinal chemistry 54 (11), 3895-3902, 2011 | 307 | 2011 |
| Opening the lid on piano-stool complexes: An account of ruthenium (II)–arene complexes with medicinal applications AA Nazarov, CG Hartinger, PJ Dyson Journal of Organometallic Chemistry 751, 251-260, 2014 | 283 | 2014 |
| Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds MG Mendoza-Ferri, CG Hartinger, RE Eichinger, N Stolyarova, K Severin, ... Organometallics 27 (11), 2405-2407, 2008 | 205 | 2008 |
| Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity MG Mendoza-Ferri, CG Hartinger, MA Mendoza, M Groessl, AE Egger, ... Journal of medicinal chemistry 52 (4), 916-925, 2009 | 199 | 2009 |
| Carbohydrate-metal complexes and their potential as anticancer agents CG Hartinger, AA Nazarov, SM Ashraf, PJ Dyson, BK Keppler Current medicinal chemistry 15 (25), 2574-2591, 2008 | 199 | 2008 |
| Metal-based inhibition of poly (ADP-ribose) polymerase− the guardian angel of DNA F Mendes, M Groessl, AA Nazarov, YO Tsybin, G Sava, I Santos, ... Journal of medicinal chemistry 54 (7), 2196-2206, 2011 | 164 | 2011 |
| In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate‐based ligands I Berger, M Hanif, AA Nazarov, CG Hartinger, RO John, ML Kuznetsov, ... Chemistry–A European Journal 14 (29), 9046-9057, 2008 | 140 | 2008 |
| Maltol‐Derived Ruthenium–Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand–Metal Bond Stability on Anticancer Activity In Vitro W Kandioller, CG Hartinger, AA Nazarov, C Bartel, M Skocic, MA Jakupec, ... Chemistry–A European Journal 15 (45), 12283-12291, 2009 | 137 | 2009 |
| Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic … MG Mendoza-Ferri, CG Hartinger, AA Nazarov, RE Eichinger, ... Organometallics 28 (21), 6260-6265, 2009 | 110 | 2009 |
| Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules M Hanif, AA Nazarov, A Legin, M Groessl, VB Arion, MA Jakupec, ... Chemical communications 48 (10), 1475-1477, 2012 | 107 | 2012 |
| From Pyrone to Thiopyrone Ligands− Rendering Maltol-Derived Ruthenium (II)− Arene Complexes That Are Anticancer Active in Vitro W Kandioller, CG Hartinger, AA Nazarov, ML Kuznetsov, RO John, ... Organometallics 28 (15), 4249-4251, 2009 | 104 | 2009 |
| Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta AK Renfrew, AD Phillips, AE Egger, CG Hartinger, SS Bosquain, ... Organometallics 28 (4), 1165-1172, 2009 | 103 | 2009 |
| Osmium (II)–versus ruthenium (II)–arene carbohydrate-based anticancer compounds: similarities and differences M Hanif, AA Nazarov, CG Hartinger, W Kandioller, MA Jakupec, VB Arion, ... Dalton Transactions 39 (31), 7345-7352, 2010 | 100 | 2010 |
| DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media O Nováková, AA Nazarov, CG Hartinger, BK Keppler, V Brabec Biochemical pharmacology 77 (3), 364-374, 2009 | 91 | 2009 |
| Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity AA Nazarov, SM Meier, O Zava, YN Nosova, ER Milaeva, CG Hartinger, ... Dalton Transactions 44 (8), 3614-3623, 2015 | 84 | 2015 |
| Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety W Kandioller, CG Hartinger, AA Nazarov, J Kasser, R John, MA Jakupec, ... Journal of Organometallic Chemistry 694 (6), 922-929, 2009 | 75 | 2009 |
| From hydrolytically labile to hydrolytically stable RuII–arene anticancer complexes with carbohydrate-derived co-ligands M Hanif, SM Meier, W Kandioller, A Bytzek, M Hejl, CG Hartinger, ... Journal of Inorganic Biochemistry 105 (2), 224-231, 2011 | 74 | 2011 |
| Organometallic antitumour agents with alternative modes of action A Casini, CG Hartinger, AA Nazarov, PJ Dyson Medicinal Organometallic Chemistry, 57-80, 2010 | 73 | 2010 |
| A glucose derivative as natural alternative to the cyclohexane‐1, 2‐diamine ligand in the anticancer drug oxaliplatin? I Berger, AA Nazarov, CG Hartinger, M Groessl, SM Valiahdi, MA Jakupec, ... ChemMedChem: Chemistry Enabling Drug Discovery 2 (4), 505-514, 2007 | 73 | 2007 |
